TCT 2024 Late-Breaking Science Collection

Published: 17 October 2024

  • Views:

    Views Icon 2697

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Keep informed with our video collection unveiling data from the Transcatheter Cardiovascular Therapeutics Conference in Washington. With expert insights on late-breaking trials and critical findings, you won't want to miss our #TCT24 coverage.

  • For practice-focused reviews of the most anticipated trials, watch our recurring View From the Thoraxcenter series, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL).
  • Our short Expert Interviews with select faculty offer focused data analysis and take-home messages for practice.
  • To delve deeper into insights on the most pertinent trials, catch our Highlights.

Dive into the latest cardiology research with our upcoming TCT Conference coverage.

More from this programme

Part 1

View From the Thoraxcenter: What's Hot at TCT 24?

1 session
View from the Thoraxcenter: TCT 24 Late-breaking Preview Watch now

Part 2

Expert Interviews

9 sessions
SIRONA: Sirolimus- vs. Paclitaxel-Coated Balloon Angioplasty in the Femoropopliteal Artery Watch now
TAVR UNLOAD: Transcatheter Aortic Valve Replacement in Patients with Heart Failure and Moderate Aortic Stenosis Watch now
EVOLVED: Early Intervention in Patients with Asymptomatic Severe Aortic Stenosis and Left Ventricular Decompensation Watch now
MATTERHORN: Transcatheter Repair Versus Surgery in Mitral Regurgitation Watch now
INFINITY-SWEDEHEART: DynamX Bioadaptor in Patients with Complex Lesions Watch now
Pooled Analysis of the RHEIA and PARTNER 3 Trials: Transcatheter vs. Surgical Aortic Valve Replacement in Women Watch now
CLASP IID: Two-Year Outcomes of Transcatheter Edge-to-Edge Repair for Degenerative Mitral Regurgitation Watch now
ECLIPSE: Orbital Atherectomy vs. Conventional Balloon Angioplasty in Calcified Coronary Arteries Prior to DES Implantation Watch now
TRISCEND II: Transcatheter Valve Replacement vs. Optimal Medical Therapy for Severe Tricuspid Regurgitation Watch now

Part 3

Highlights

2 sessions
5 Trials That Will Change My Practice with Dr Mirvat Alasnag Watch now
2 Trials That Will Change My Practice with Dr Sahil Parikh Watch now

About the episode

TCT Conference 2024 - Safety and efficacy outcomes of transcatheter aortic valve replacement (TAVR) in addition to optimal heart failure therapy (OHFT) compared to OHFT alone in patients with heart failure and moderate aortic stenosis.

Dr Nicolas M Van Mieghem (Erasmus University Medical Center, Rotterdam, NL) joins us onsite at TCT Conference to discuss the findings from TAVR UNLOAD (NCT02661451).

TAVR UNLOAD is an international, multicenter, open-label clinical trial, where patients with heart failure (HF) and moderate aortic stenosis were randomised 1:1 to receive either TAVR (Edwards SAPIEN 3 Transcatheter Heart Valve) in addition to OHFT or OHFT alone. 600 patients were enrolled in the trial and were followed-up at 1, 6, and 12 months, as well as 2 years after randomisation. The primary outcome measures were the hierarchical occurrence of all-cause death, disabling stroke, hospitalisations related to HF, symptomatic aortic valve disease or nondisabling stroke, and change in the Kansas City Cardiomyopathy Questionnaire at one year.

Results showed that TAVR in this patient group was safe, but did not affect the primary hierarchical composite endpoint at a median follow up of 23 months. TAVR resulted in more wins in the primary endpoint at one year follow up, driven by clinically meaningful improvement in quality of life compared to clinical aortic stenosis surveillance. 

Interview Questions:

  1. What is the reasoning behind the trial?
  2.  Could you tell us about the patient population and study design for TAVR UNLOAD?
  3. What were the key findings?
  4. How should these findings impact clinical practice?
  5. What further research is needed?

Recorded on-site at TCT Conference in Washington, 2024.

Editors: Yazmin Sadik, Jordan Rance
Videographers: David Ben-Harosh, Oliver Miles

Support: This is an independent interview produced by Radcliffe Cardiology.

Faculty Biographies

Nicolas M Van Mieghem

Nicolas M Van Mieghem

Medical Director

Prof Nicolas Maria Van Mieghem is an Interventional cardiologist at Thoraxcenter, Erasmus MC, Rotterdam, NL decided to pursue a career that would help others. “I enjoy the feeling of being able to help someone or do something important for them". His father was a general cardiologist and one of his biggest influences early in his career.

Prof Van Mieghem initially intended to train as a cardiac surgeon but decided to specialise in interventional cardiology instead, following advice from a mentor. This decision was cemented when he read the first-in-human case report of transcatheter aortic valve implantation (TAVI) in Circulation by Alain Cribier in 2002. Prof Van Mieghem believes that great cardiologist genuinely cares for their patients. He names Gary Roubin, Dr Manu Malbrain and Professor Patrick Serruys among his mentors. 

His current research focuses on cerebral embolic protection during TAVI and the search for improved…

View full profile

Comments

You must be to comment. If you are not registered, you can register here.